A man in his 80s with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma was started on combination therapy with atezolizumab, an immune checkpoint inhibitor, and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor. Three days after the first cycle, he developed
Tokushige et al. (Mon,) studied this question.